feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Risky Meds Still Given to Dementia Patients

Risky Meds Still Given to Dementia Patients

13 Jan

•

Summary

  • Many dementia patients receive risky medications despite warnings.
  • Prescriptions for these drugs declined but remain high.
  • Over two-thirds lacked documented need in 2021.
Risky Meds Still Given to Dementia Patients

Despite long-standing clinical warnings against central nervous system stimulants for older patients due to risks like delirium and falls, research reveals their continued use in dementia patients across the U.S. A study analyzing Medicare data between 2013 and 2021 found approximately 25% of enrolled dementia patients received at least one "potentially inappropriate" medication, including antipsychotics and certain antidepressants.

Although prescriptions saw a decline from roughly 20% to 16% over the study period, they remained higher for patients with cognitive impairment as of 2021. Researchers noted that over two-thirds of patients receiving these drugs lacked a documented clinical indication in 2021, suggesting a high rate of potentially harmful prescribing, especially for individuals with heightened vulnerability to adverse effects.

The study, which included data from the Health and Retirement Study and was extrapolated to the U.S. population, did not account for Medicare Advantage plans. Scientists acknowledged that doctors might have prescribed these medications as a "least worst" option for dementia symptoms often underreported in Medicare claims, underscoring complex challenges in optimizing care quality and safety for millions of older Americans.

trending

HYDRAA Prajavani receives complaints

trending

HCL Tech Q3 results

trending

Renegades retire Mohammad Rizwan

trending

Delhi temperature drops amid cold

trending

Tata Punch facelift launched

trending

Amagi Media Labs IPO opens

trending

TNSTC operates festival special buses

trending

Punjab sets 346-run target

trending

LeBron, Doncic play Kings

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Yes, new research indicates that a significant number of dementia patients in the U.S. are still being prescribed medications deemed risky due to potential side effects like delirium and falls.
Central nervous system stimulants can increase the risk of delirium, falls, and hospitalizations in older patients, as highlighted by decades of clinical guidelines.
Researchers estimated that roughly 25% of dementia patients enrolled in Medicare parts A, B, and D received at least one potentially inappropriate medication between 2013 and 2021.

Read more news on

Healthside-arrow

You may also like

Millions Warned of Hidden Drug Dangers

9 Jan • 39 reads

article image

Generic ADHD Drug Boosts US Access

8 Jan • 26 reads

article image

Exercise Beats Depression: New Study Finds

8 Jan • 20 reads

article image

ADHD Meds Boost Alertness, Not Focus Directly

26 Dec, 2025 • 105 reads

article image

Diabetes Drugs May Cut Epilepsy Risk

14 Dec, 2025 • 151 reads